TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN

NCT ID: NCT04128722

Last Updated: 2025-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-02-14
• Study Completion Date: 2025-01-08

Brief Summary

Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported. The natural history of LMLMs is progressive worsening. LMLMs complex management requires multidisciplinary care in specialised centres, and the "wait-and-see" approach is frequently used. In complicated lymphatic malformations, whatever the location, treatment with oral sirolimus, an mTOR (mammalian Target of Rapamycin) inhibitor, is often used.

Topical sirolimus is a known effective treatment for some cutaneous conditions such as angiofibromas in tuberous sclerosis. Topical applications of sirolimus on the buccal mucosae have been reported in erosive lichen planus and oral pemphigus vulgaris with good tolerance and none to slight detectable blood sirolimus concentrations.

The objective of this study is to evaluate the efficacy and safety of a 1mg/mL sirolimus solution applied once daily on mild to moderate lingual microcystic lymphatic malformation in children and adults after 4, 8, 12, 16, 20 and 24 weeks of treatment as compared to usual care (no treatment).

Detailed Description

This is a randomized, open-labelled, multicenter pilot study using an individually randomized stepped wedge design over a 24 weeks period to evaluate topical application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation that do not require systemic treatment, the experimental intervention versus usual care (no treatment), the control condition.

In this design, subjects are included in a cohort where at a randomized time (W0, W4, W8 or W12), they switch from an observational period to the interventional period.

All subjects will be followed for 24 weeks

Conditions

Lingual Microcystic Lymphatic Malformations

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Sirolimus 1mg/mL

Application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation, the experimental intervention versus usual care (no treatment), the control condition.

Group Type: EXPERIMENTAL

Sirolimus Oral Liquid Product 1mg/mL

Intervention Type: DRUG

0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation

Control condition

Usual care, i.e. no intervention

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Sirolimus Oral Liquid Product 1mg/mL

0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation

Intervention Type: DRUG

Other Intervention Names

Experimental treatment

Eligibility Criteria

Inclusion Criteria

• Participants ≥ 5 years of age
• Lingual microcystic lymphatic malformation that does not require systemic treatment, assessed by clinical examination and head-and-neck MRI imaging prior to study enrolment, with or without underlying syndromic malformation (CLAPO for instance)
• Participants covered by or having the rights to social security
• Written informed consent obtained from participant and participant's legal representative if participant is under 18
• Ability for participant to comply with the requirements of the study

Exclusion Criteria

• Patients with a lymphatic malformation requiring a continued background therapy (involving deep organs)
• Secondary lymphatic malformations (lymphangiectasia post-radiotherapy, etc)
• Previous treatment with systemic or topical mTOR (mammilian target of rapamycin) inhibitors within 12 months before inclusion (half-life of oral sirolimus is 60 days in adults).
• Previous treatment with oral or topical steroids within 10 days before inclusion (half-life of corticosteroids is 12-36 hours)
• Immunosuppression (immunosuppressive disease or immunosuppressive treatment)
• Ongoing neoplasia
• Active chronic infectious disease (Hepatitis-B virus, Hepatitis-C virus, HIV, etc)
• Local necrosis
• Local fungal, viral (herpes simplex virus, varicella zoster virus, etc) or bacterial infection on the site of the LMLM (based on clinical examination)
• Known allergy to one of the components of the sirolimus solution
• Soy bean or Peanut allergy
• Pregnant or breastfeeding women
• Women of child-bearing potential (including teenagers) not using a reliable contraceptive method until the end of the study and three month after the end of the study or sirolimus discontinuation.
• Already involved in another therapeutic trial

• Minimum Eligible Age: 5 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Tours

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Annabel MARUANI, MD-PhD

Role: STUDY_DIRECTOR

University Hospital of TOURS;INSERM 1246 SPHERE

Locations

Univsersity of TOURS _ Service de Dermatologie

Tours, Indre et Loire, France

Hospital NECKER -AP-HP - Dermatology

Paris, , France

Countries

France

References

Marchand A, Caille A, Gissot V, Giraudeau B, Lengelle C, Bourgoin H, Largeau B, Leducq S, Maruani A. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial. Trials. 2022 Jul 8;23(1):557. doi: 10.1186/s13063-022-06365-y.

Reference Type: DERIVED

PMID: 35804404 (View on PubMed)

Other Identifiers

2019-001530-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

DR190041-TOPGUN

Identifier Type: -

Identifier Source: org_study_id